| |
|
January 5, 2004 |
| |
| If
you are unable to view these articles or access the links,
please visit the ASBMT Web Site at
www.asbmt.org to read this
issue. To be removed from this distribution list, please see
instructions at bottom. |
| |
 |
Top
Stories |
| |
|
 |
Legislation and Regulation |
| |
|
 |
Clinical
Research |
| |
|
 |
Pharmaceutical
News |
| |
|
 |
Association
News |
| |
|
 |
Calendar |
|
|
 |
eNews
Archives |
|
|
|
|
|
|
|
|
|
|
|
|
|
Tandem BMT Meetings
Feb 13 - 17, 2004
Orlando, Florida
|
 |
|
|
|
|
|
|
|
(Note: Answers to this interactive poll are anonymous.)
|
|
|
|
Last Month's
Poll Results
How
are intensive care patients managed at your transplant
center?
|
Our intensive care patients are treated in our
transplant unit. |
(173) 25% |
|
|
|
|
Our
intensive care patients are transferred to an ICU,
either within the institution or at a nearby hospital. |
(442)
64% |
|
|
|
|
Other |
(78) 11% |
|
Calendar |
•
January
American Society of Transplantation (AST)
8th Annual Winter Symposium
Jan. 15-18
Westin Kierland Resort
Scottsdale, Ariz.
•
February
6th International Congress on New Trends in Immunosuppression
Feb. 5-8
Salzburg Congress Centre
Salzburg, Austria
Tandem BMT Meetings
(Combined ASBMT and IBMTR/ABMTR annual meetings)
Feb. 13-17
Coronado Springs Resort
Orlando, Fla.
•
March
American Association for Cancer Research (AACR)
95th Annual Meeting
March 27-31
Orange County Convention Center
Orlando, Fla.
European Group for Blood and Marrow Transplantation (EBMT)
30th Annual Meeting
March 28 - 31
Palau de Congressos de Catalunya
Barcelona, Spain
•
April
American Society of Pediatric Hematology/Oncology (ASPH/O)
17th Annual Scientific Meeting
April 29-May 2
Westin St. Francis Hotel
San Francisco
•
May
International Society for Cellular Therapy (ISCT)
10th Annual Meeting
May 7-10
The Burlington Hotel
Dublin, Ireland
World Marrow Donor Association (WMDA)
5th International Donor Registry Conference
May 26-29
Keio University Mita Campus
Tokyo, Japan
• June
Canadian Blood and Marrow Transplant Group (CBMTG)
Biennial Meeting
June 3-6
London Convention Centre
London, Ontario
American Society for Clinical Oncology (ASCO)
40th Annual Meeting
June 5-8
Ernest N. Morial Convention Center
New Orleans
International Society for Stem Cell Research (ISSCR)
2nd Annual Meeting
June 10-13
Boston Seaport Hotel
Boston
• July
Federation of Clinical Immunology Societies (FOCIS)
4th Annual Conference
July 18-23
Palais de Congres de Montreal
Montreal, Quebec
International Society for Experimental Hematology (ISEH)
33rd Annual Scientific Meeting
July 17-20
New Orleans Marriott
New Orleans
• October
American Society for Histocompatibility and Immunogenetics (ASHI)
30th Annual Meeting
Oct. 1-6
San Antonio Convention Center
San Antonio, Texas
American Association of Blood Banks (AABB)
57th Annual Meeting
Oct. 23-26
Baltimore
American Society of Human Genetics (ASHG)
54th Annual Meeting
Oct. 26-30
Toronto, Canada
2005
Tandem BMT Meetings
(Combined ASBMT and IBMTR/ABMTR annual meetings)
Feb. 10-14
Keystone Resort
Keystone, Colo.
|
|
|
|
|
|
|
| |
Top
Stories |
| |
Gene identified that controls development of embryonic nerve
cells
Researchers have identified a gene in the cerebral cortex
that appears to control the developmental clock of embryonic
nerve cells, paving the way for tissue replacement therapy in
the central nervous system. By manipulating this gene,
scientists at the New York University School of Medicine tricked
the brains of embryonic mice into producing cortical cells,
according to an article in the Jan. 2 issue of the journal
Science.
 |
|
|
Substance identified to induce
dedifferentiation in muscle cells
Scientists at the Scripps Research Institute have identified
a synthetic compound – called reversine -- that can induce cells
to undergo dedifferentiation, turning adult muscle cells into
multipotent precursor cells. The researchers hope this finding
will help prompt epimorphic regeneration, similar to how
amphibians regenerate lost tails and limbs. The results will be
published in an upcoming issue of the Journal of the American
Chemical Society.
 |
| |
Chemical derived from sea snails stops human
embryonic stem cell development
By treating human embryonic stem cells with a substance
called BIO, derived from sea snails, scientists at Rockefeller
University have stopped the cells from developing into
specialized adult cells. BIO activates the Wnt pathway and may
eliminate the need for mouse support cells and the associated
problems of contaminating proteins.
 |
| |
Martin Evans, discoverer of stem cells,
receives knighthood
Martin Evans, professor of mammalian genetics at Cardiff
University, has been named a Fellow of the Royal Society for his
services to medical science. Evans is credited with discovering
embryonic stem cells in 1981, and he also created a method to
alter genes in mice, among other breakthroughs.
 |
| |
| |
|
A
Word from President Joseph Antin, M.D.
Have You Voted?
If you are a Member of our society, you should have
received a ballot in the mail within the past week or so
for choosing ASBMT officers and directors. To my
knowledge, few medical societies are as democratic as
ours.
In many national associations, the officers and directors
are selected by their Board, which tends to be
self-perpetuating. Others present a single slate of
nominees for office, one candidate per position, so the
outcome is virtually decided before the balloting begins.
Still others have a house of delegates, which is fine but
doesn’t provide for direct participation by the members.
I’ve always been proud that our Society gives members a
contest for every open officer and director position.
Members have a real say in who will be the leaders of
their Society. One of the benefits has been a healthy
turnover of leadership and a constant infusion of new
ideas and experiences.
If you think your ballot doesn’t count (for instance, if
you live in Massachusetts), I can tell you about an
election not long ago that was won by a single vote. It
was a near miss “constitutional crisis” for our Society
because we had no policy on how to break a tie. Since
then, the ASBMT Bylaws have been amended to provide a
tie-breaking procedure. At the time of the amendment, the
Board received several amusing recommendations, including
the suggestion of a duel between tied candidates. We can
hope that this wit isn’t reflective of the general sense
of humor of our members.
The deadline for returning your ballot is Jan. 14. You
know what to do.
Conventional Intimacies
Last month in San Diego, as a perennial ASH attendee, I
was once again struck by the quality of the work but the
inability to see what I wanted to see. Simultaneous
sessions are often too simultaneous for me to move back
and forth effectively, particularly given the distances
between some of the meeting rooms. If you miss a talk,
it’s hard to connect with the author to chat about it
later.
The posters, too, are often quite interesting, but the
sheer numbers and noise makes it difficult to take it all
in. Information overload. This is in contrast to our own
Tandem BMT Meetings, where time and space do not require
Stephen Hawking to set your itinerary. Our more intimate
meeting allows us all to digest some of the data and meet
to establish collaborations. I encourage everyone to make
their travel arrangements early – remembering that
Presidents’ weekend coincides with our meeting.
A Cruise Anyone?
Speaking of the Tandem BMT Meetings, what would you think
of holding the annual February event on a cruise ship in
the Caribbean?
As you probably know, we have a pattern of meeting every
second year in Keystone, Colo. In the alternate years we
head to a warm climate. The year 2008 will be a
non-Keystone year. During our recent Board of Directors
meeting, it was suggested that we consider placing the
entire meeting on a privately booked cruise ship, sailing
perhaps out of Miami or Fort Lauderdale.
There are pros and cons. One of the big concerns is that
participants, and speakers, couldn’t come and go as
easily. But maybe that is a “pro” as well. We will need to
look into the cost of such a venture, of course. Please
let us know your thoughts, using the ASBMT Monthly Poll to
the left of this column.
On behalf of the Society’s officers and directors, I
extend to you and your family our best wishes for a very
happy and productive New Year.
– Joe |
|
| |
Legislation and Regulation |
| |
New Jersey assembly passes legislation allowing embryonic
stem cell research
The New Jersey State Assembly passed a bill allowing
embryonic stem cell research with a vote of 41 to 31, and Gov.
Jim McGreevey is expected to sign the bill into law. Passage of
the bill, which outlaws cloning, will make New Jersey only the
second state to allow such research.
 |
| |
Clinical
Research |
| |
Human embryonic stem cells may cure Parkinson’s disease
Genetically modified human embryonic stem cells can cure
Parkinson’s disease in rats, according to a Korean study
published in the Dec. 19 issue of the journal Neuroscience
Letters. Researchers injected two genes related to generating
dopamine into human embryonic stem cells and implanted them into
the brains of rats suffering from Parkinson’s disease; normal
muscle movement returned six weeks after the procedure.

Administering myoblasts via catheter proves effective in
repairing heart
In five patients suffering heart failure after a heart
attack, threading a catheter through a leg artery and into the
heart and injecting myoblasts directly into the affected area
repaired the damage. In a study published in the Dec. 17 issue
of the Journal of the American College of Cardiology,
patients showed improvement in heart output at three and six
months, as well as significant thickening of the heart wall near
the injection site.

Single antibiotic dose appears best in children undergoing
stem cell transplant
As in adults, a single dose of tobramycin in children under
age 18 undergoing a stem cell transplant is more effective than
the standard three-dose regimen, says a report in the Dec. 17
issue of the Journal of the National Cancer Institute. In
the 60 children studied, the single dose also resulted in less
damage to the kidneys.

Mini stem cell transplants provide remission from recurrent
mantle cell lymphoma
Mini, non-myeloablative allogeneic stem cell transplants
provide sustained remissions in patients suffering from
recurrent mantle cell lymphoma, according to the results of a
study published in the Dec. 1 issue of the Journal of
Clinical Oncology. A clinical trial at the M.D. Anderson
Cancer Center in 18 patients showed complete remission in 17
patients and progression-free survival of 82 percent at
follow-up an average of more than 26 months later.
 |
| |
Pharmaceutical News |
|
|
|
Amgen Inc. buys $20 million stake in ViaCell Inc.
In exchange for a $20 million share, Boston-based ViaCell
Inc. will gain licenses to research several of Amgen Inc.’s
growth factors. In addition, Amgen will have the option to
cooperate in the development of future ViaCell projects.

Positive results for Velcade bring trials to an early end
Millennium Pharmaceuticals Inc., manufacturer of Velcade (bortezomib),
is bringing the control arm of the phase III Apex trial to an
early halt, based on the results of an independent data
monitoring committee. Because of a significantly significant
improvement in time to disease progression in patients receiving
Velcade, patients currently receiving dexamethasone can
immediately cross over to Velcade.
 |
|
|
Association
News |
| |
|
Reserve housing by Jan. 12 for Tandem BMT Meetings
The deadline is Jan. 12 for housing for the 2004 Tandem BMT
Meetings, Feb. 13-17 in Orlando. After that date, sleeping
accommodations at special convention rates are on a “space
available” basis. A Housing Reservation Form can be downloaded
from the ASBMT Web site, or call Coronado Springs Resort
reservations at (407) 939-1020. The special conference rate is
$138 for a single or double.

New Investigator Award will be presented for LDI project
The recipient of the ASBMT/Fujisawa New Investigator Award is
Sijie Lu, Ph.D., at M.D. Anderson Cancer Center for work on
“Selective Expansion of Anti-Leukemic CTL for Donor Lymphocyte
Infusion.” The $25,000-per-year award was announced by ASBMT
President Joseph H. Antin. Renewable for a second year, the
award is funded by an unrestricted educational grant from
Fujisawa Healthcare Inc.
Travel grants announced for Tandem BMT Meetings
The ASBMT Board of Directors has awarded travel grants of
$1,000 each to the young investigators invited to give oral
presentations at the 2004 Tandem BMT Meetings. This year, 40 of
the 66 oral abstracts will be presented by young investigators –
those not more than five years past an M.D. or Ph.D. degree.

Free ASBMT membership for trainees
Post-doctoral fellows and physicians-in-training for blood
and marrow transplantation are eligible for free ASBMT
membership in 2004. The recruitment program has increased
in-training enrollments in the Society from 26 to 123 in the
past several months.

|
| |
| |
|